Daphne Quimi - 11 Jan 2023 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Reporting relationship: Chief Financial Officer
Issuer ticker: FOLD
Reported as of: 11 Jan 2023
Net transaction value: -$355,371
SEC form: 4
Accepted by SEC: 13 Jan 2023, 16:16:22 UTC
Prior SEC filing: 06 Jan 2023
Next SEC filing: 19 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Christian Formica, Attorney-in-Fact

Key filing fact

Daphne Quimi filed Form 4 for AMICUS THERAPEUTICS, INC. (FOLD) on 13 Jan 2023.

Key facts

This page summarizes Daphne Quimi's Form 4 filing for AMICUS THERAPEUTICS, INC. (FOLD).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 13 Jan 2023, 16:16.

Change

Previous filing in this sequence was filed on 06 Jan 2023.
Current net transaction value: -$355,371.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FOLD transaction

Common Stock

Award

Transaction value: $0
Shares: +58,824
Change %: +15%
Price: $0.000000
Shares after: 440,020
Date: 11 Jan 2023
Ownership: Direct
Footnotes: F1

FOLD transaction

Common Stock

Tax liability

Transaction value: $355,371
Shares: -29,565
Change %: -6.7%
Price: $12.02
Shares after: 410,455
Date: 11 Jan 2023
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Granted for the achievement of the 2020 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors.